232nd ENMC international workshop: Recommendations for treatment of mitochondrial DNA maintenance disorders. 16 - 18 June 2017, Heemskerk, The Netherlands
- PMID: 35641351
- DOI: 10.1016/j.nmd.2022.05.008
232nd ENMC international workshop: Recommendations for treatment of mitochondrial DNA maintenance disorders. 16 - 18 June 2017, Heemskerk, The Netherlands
Conflict of interest statement
Declaration of Competing Interest RM, MH, and YC report grants, non-financial support, personal fees and other suppot from Zogenix/UCB. In addition, RM and MH have a patent “Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes” (PCT/US16/038110) with royalties paid by Zogenix/UCB; MH reports grants and other support from Entrada Therapeutics. RM and YC have a patent “Treatment of mitochondrial diseases” (PCT/EP2016/062636) with royalties paid by Zogenix/UCB.These relationships for MH are de minimus for Columbia University Irving Medical Center and for RM and YC are de minimus for Vall d'Hebron Research Institute and CIBERER.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical